F123 Complex Medical Dermatology Cases: Pearls and Pitfalls
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Many patients present with challenging skin manifestations posing diagnostic and therapeutic dilemmas. Using a case-based approach featuring complex medical dermatoses (including atopic dermatitis, lupus, dermatomyositis, vasculitis, and hidradenitis suppurativa), this session will highlight clinical pearls in making the diagnosis and elaborating treatment regimens as well as pitfalls to avoid. Management strategies based on the latest data from the literature will be reviewed, in addition to useful novel diagnostic tests.
LEARNING OBJECTIVES
Recognize subtleties in clinical presentation when formulating differential diagnoses in select complex medical dermatoses
Apply "tricks of the trade" when elaborating a management plan for treating select complex medical dermatoses
SPEAKERS
Benjamin F. Chong, MD, MSc, FAAD
Christina Lam, MD, FAAD
Robert Micheletti, MD, FAAD
Adnan Mir, MD, PhD, FAAD
Gregory Orlowski, MD, PhD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Benjamin F. Chong, MD, MSc, FAAD
Amgen – Other(Honoraria); Biogen – Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant(Honoraria); Daavlin Company – Investigator(Grants/Research Funding); EMD Serono – Consultant(Honoraria); Horizon Pharma, Inc. – Consultant(Honoraria); Lupus Research Alliance – Consultant (1099 relationship)(Honoraria); MAPI Research Trust – Other(Patent royalties or other compensation for Intellectual Property Rights); Pfizer Inc. – Investigator(Grants/Research Funding);
Christina Lam, MD, FAAD
Biogen – Consultant (1099 relationship)(Fees), Investigator(Fees);
Robert Micheletti, MD, FAAD
Acelyrin – Investigator(Grants/Research Funding); Boehringer Ingelheim – Investigator(Grants/Research Funding); Cabaletta Bio – Investigator(Grants/Research Funding); InflaRx – Investigator(Grants/Research Funding); Vertex Pharmaceuticals, Inc. – Consultant(Fees);
Adnan Mir, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Gregory Orlowski, MD, PhD, FAAD
No financial relationships exist with ineligible companies.